Founded in 1989, Guangdong bidi Pharmaceutical Co., Ltd. is located in Kaiping, a famous hometown of overseas Chinese in the central and Western Pearl River Delta of China. It is a pharmaceutical enterprise that produces and manages Chinese and Western patent medicines and pharmaceutical and chemical raw materials. It is one of the first batch of GMP certified enterprises in Guangdong Province, one of the 20 key enterprises in the pharmaceutical industry in Guangdong Province, post doctoral innovation and practice base in Guangdong Province, Guangdong technology research and development center, Guangdong Province Provincial famous trademark and other state-level high-tech enterprises.
The company is a garden style layout with beautiful environment. Among them, the production workshop is divided into the headquarters workshop and a branch factory. The headquarters workshop has a dedicated workshop, such as oral solid, large volume injections, sprays, penicillin, and a number of automatic production lines approved by GMP. The annual output of tablets, capsules and granules in the workshop of the General Factory is 2 billion, 500 million and 400 million bags respectively, and the annual output of large volume injection is 30 million bottles. One branch is dedicated to the production of omeprazole pellets intermediate and used to replace imported auxiliary materials: methacrylic acid ethyl acrylate copolymer water dispersion. At present, the company has a series of anti bacteria, anti-virus, cardio cerebrovascular, analgesic and anti-inflammatory, digestive system, respiratory system and other therapeutic drugs, with a total of more than 140 varieties, of which more than 50 varieties are in production. The company has more than 600 employees, including more than 250 technical personnel above junior college. After more than 20 years of unremitting efforts of all employees, the company has developed into a modern pharmaceutical enterprise with total assets of more than 600 million yuan. In 2018, the sales revenue reached 459 million yuan, with a total tax payment of over 56.44 million yuan. For this reason, the company has been awarded with outstanding contribution by the government finance and tax department for many times.
The company has been carrying out scientific and efficient operation and management on generic drug research and development, process prescription design, drug testing and quality control, and automatic clean production. In terms of investment in new dosage forms and new technologies, the company mainly focuses on projects with few domestic and high technical difficulties, and invests no less than 10 million yuan for research and development of new products every year.